

December 5, 2025

To whom it may concern:

Company Name: TOHO HOLDINGS CO.,LTD.
Corporate Representative: Hiromi Edahiro, Representative Director,
President and CEO
(Prime Market of Tokyo Stock Exchange
Securities Code: 8129)
Contact: Makoto Kawamura, Executive Corporate Officer
and General Manager, Corporate Strategy
Division
(TEL: 81-3-6838-2803)

Notice Regarding Launch of KYOSOMIRAI PHARMA of
1 Ingredient / 3 Products of Generic Drugs

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Yasuyuki Kumada), the wholly-owned subsidiary involved in pharmaceuticals manufacturing and sales business, has launched 1 ingredient / 3 products of generic drugs today on December 5, 2025 as below.

New products list

Class	Product Name	Original Brand Name
Anti-epileptic agent	Lacosamide Tablets 50mg/100mg “Chemiphar”	VIMPAT® TABLETS 50mg/100mg
	Lacosamide Dry Syrup 10% “Chemiphar”	VIMPAT® DRY SYRUP 10%